These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30309697)

  • 61. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
    Nherera L; Calvert NW; Demott K; Humphries SE; Neil HA; Minhas R; Thorogood M
    Curr Med Res Opin; 2010 Mar; 26(3):529-36. PubMed ID: 20014994
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Statin intolerance].
    Tonstad S
    Tidsskr Nor Laegeforen; 2017 Jan; 137(1):36-38. PubMed ID: 28073228
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.
    Galema-Boers AMH; Lenzen MJ; Sijbrands EJ; Roeters van Lennep JE
    J Clin Lipidol; 2017; 11(3):674-681. PubMed ID: 28506389
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
    Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
    Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
    Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New concepts in the management of dyslipidaemiaa.
    Gencer B; Rodondi N; Mach F
    Swiss Med Wkly; 2016; 146():w14378. PubMed ID: 27878791
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?].
    Parhofer KG
    Herz; 2016 May; 41(3):217-23. PubMed ID: 26961236
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial.
    Hong SJ; Jeong HS; Ahn JC; Cha DH; Won KH; Kim W; Cho SK; Kim SY; Yoo BS; Sung KC; Rha SW; Shin JH; Han KR; Chung WS; Hyon MS; Lee HC; Bae JH; Rhee MY; Kwan J; Jeon DW; Yoo KD; Kim HS
    Clin Ther; 2018 Feb; 40(2):226-241.e4. PubMed ID: 29402522
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
    Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
    Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.
    Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY
    J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.
    Pitsavos C; Skoumas I; Tousoulis D; Metalinos G; Masoura C; Chrysohoou C; Papadimitriou L; Giotsas N; Toutouza M; Antoniades C; Stefanadis C
    Int J Cardiol; 2009 May; 134(2):280-1. PubMed ID: 18353459
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
    Thiery J; Burkhardt R
    Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.
    Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ
    Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.